US OptionsDetailed Quotes

HUMA241220P15000

Watchlist

9.27
0.000.00%

15min DelayClose Nov 25 16:00 ET

0.00High0.00Low

Humacyte Stock Discussion

102875548

10 hours ago

$Humacyte (HUMA.US)$
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.

Jaguar8

22 hours ago

MY MONDAY WATCHLIST. These are the stocks with POSSIBLE run between 20% and up based on news, chart, or promotion.

NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...

Trytosaveabit

Nov 22 07:06

Watching

$Humacyte (HUMA.US)$ Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Benzinga· 3 mins ago

Jaguar8

Nov 22 07:00

NEWS

$Humacyte (HUMA.US)$
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...

104983812

Nov 19 09:17

$Humacyte (HUMA.US)$ shd i sell this shit stock ?

Trytosaveabit

Nov 18 07:07

Update

$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...

convivial Penguin_29

Nov 8 18:14

Share Your Profit/Loss

104983812

Nov 8 09:38

$Humacyte (HUMA.US)$
what happened? the earnings suck but now the stock is rising

10baggerbamm

Oct 30 10:05

$Humacyte (HUMA.US)$ Look at the price target from two days ago..$25..
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.

Jaguar8

Oct 28 06:18

NEWS

$Humacyte (HUMA.US)$
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...

No comment yet